Purpose Beginning in 2018, biomarkers including estrogen receptor (ER) status were
incorporated in the 8th AJCC staging system. ER expression levels were not considered in …

Purpose While the estrogen receptor (ER) is the single most widely used biomarker to
evaluate breast cancer outcomes, aspects of ER marker biology remain poorly understood …

Context* Testing patients for estrogen-receptor (ER) expression has become an important
factor in the prognosis and prediction of breast cancer. Many studies have shown that …

Both subtypes of estrogen receptor (ER), ERα and ERβ, are normally present in the
mammary gland. The role of ERα as a prognostic marker in breast cancer is well established …

Purpose Estrogen receptor (ER) is the key therapeutic target in breast cancer. ERβ has
recently been identified to be distinct from ERα. In contrast to ERα, the functions of ERβ in …

Abstract Background/Aims: Estrogen receptor (ER) is the prototype therapy predictive
marker in oncology. The ER is now known to exist in two main forms with similar overall …

Purpose Estrogen receptor (ER) expression in breast cancer plays an essential role in
carcinogenesis and disease progression. Recently, tumors with low level (1%–10%) of ER …

PURPOSE: The objective of the present study was to determine whether progesterone
receptor (PgR) and human epidermal growth factor receptor 2 (HER2) status differs by …

Background The prognostic role of estrogen receptor beta (ERβ) in early-stage breast
cancer is unclear. We performed a systematic review and meta-analysis to evaluate the …

Introduction The association of breast cancer patients' mortality with estrogen receptor (ER)
status (ER+ versus ER-) has been well studied. However, little attention has been paid to the …